- Hims & Hers Health, Inc. (NYSE:HIMS) is expanding its telehealth platform, focusing on high-demand treatments like GLP-1 medications and international growth, with a market capitalization of approximately $7.34 billion.
- Barclays (NYSE:BCS) recently increased its price target for Hims & Hers Health to $39.00, reflecting a positive analyst outlook and broader bullish market sentiment for the healthcare stock.
- Despite ambitious growth targets, including $6.5 billion in revenue by 2030, the company faces challenges such as high short interest (30% to 32%) and recent insider selling, which are key considerations for investors.
Hims & Hers Health, Inc. (NYSE:HIMS) is a leading telehealth company working to become a larger healthcare platform. It focuses on leveraging high demand for treatments like GLP-1 medications, growing its subscriber numbers, and expanding internationally. The company has a market capitalization of around $7.34 billion and recently partnered with Novo Nordisk (NYSE:NVO), a major pharmaceutical company, signaling strategic growth in the healthcare sector.
On June 17, 2026, Barclays (NYSE:BCS), a prominent financial institution, raised its price target for Hims & Hers Health to $39.00 from its previous target of $29.00. A price target represents an analyst’s projection of a stock’s future price. Barclays also maintained its Overweight rating, which suggests the analyst believes the telehealth stock will perform better than the average return of other stocks they cover, providing a positive investment insight.
This positive analyst view aligns with a broader shift in market sentiment. As highlighted by The Motley Fool, Wall Street is becoming more bullish on Hims & Hers Health. At the time of the Barclays announcement, the stock price was $33.10. The stock has traded within a 52-week range of $13.74 to $70.43, showing significant price movement over the past year, which is crucial for stock analysis.
The company’s own goals support this optimistic outlook and strong growth prospects. As highlighted by Seeking Alpha, Hims & Hers Health management is targeting at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. Adjusted EBITDA is a measure of operational profitability that excludes non-operating expenses like interest and taxes, providing a clearer view of core business performance and financial health.
Despite the positive sentiment and strong financial outlook, some challenges exist for the HIMS stock. The stock has a high short interest, with 30% to 32% of its available shares being bet against by investors expecting a price decline. Furthermore, over the last three months, company insiders sold $5.5 million worth of shares while buying only $1.2 million, a factor often considered in investor sentiment and insider trading analysis.
